| Literature DB >> 30639181 |
Sarah Hirsiger1, Jürgen Hänggi2, Jürgen Germann3, Matthias Vonmoos4, Katrin H Preller4, Etna J E Engeli5, Matthias Kirschner6, Caroline Reinhard4, Lea M Hulka4, Markus R Baumgartner7, Mallar M Chakravarty8, Erich Seifritz9, Marcus Herdener6, Boris B Quednow10.
Abstract
BACKGROUND: Cocaine use has been consistently associated with decreased gray matter volumes in the prefrontal cortex. However, it is unclear if such neuroanatomical abnormalities depict either pre-existing vulnerability markers or drug-induced consequences. Thus, this longitudinal MRI study investigated neuroplasticity and cognitive changes in relation to altered cocaine intake.Entities:
Keywords: Cocaine-related disorders; Cognition; Endophenotype; Prefrontal cortex
Mesh:
Substances:
Year: 2019 PMID: 30639181 PMCID: PMC6412021 DOI: 10.1016/j.nicl.2019.101652
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Fig. 1Cortical group differences at baseline.
Group differences for cortical measures for the six regions of interest. (A) Mean cortical thickness (in mm) and standard errors. All values corrected for age, verbal IQ, and ADHD-SR score. (B) Mean cortical surface area (×103 in mm2) and standard errors. All values corrected for age, verbal IQ, ADHD-SR score, and total surface area.
*P < .05 corrected for multiple comparisons. Cohen's d controls vs. cocaine users.
Fig. 2Subcortical measures at baseline.
Subcortical mean volume measures (×103 in mm3) and standard errors in cocaine users and controls. All values corrected for age, verbal IQ, ADHD-SR score, and ICV.
None of the group differences survived multiple comparisons correction. Cohen's d controls vs. cocaine users.
Demographic data and substance use information.
| Controls ( | Decreasers ( | Sustained Users ( | Controls ( | Decreasers ( | Sustained Users ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (year) | 30.0 (6.8) | 31.5 (5.5) | 32.9 (7.1) | 1.08 | 2,64 | 0.34 | pη2 = 0.03 | |||||||
| Sex (female/male) | 15/23 | 7/8 | 2/12 | 3.81 | 2 | 0.15 | V = 0.24 | |||||||
| Hair color (bl/br/blk) | 0/31/3 | 0/11/3 | 0/10/1 | 1.61 | 2 | 0.49 | V = 0.17 | |||||||
| Years between TP1/TP2 | 1.5 (1.3) | 1.8 (1.6) | 1.6 (1.5) | 0.32 | 2,64 | 0.73 | pη2 = 0.01 | |||||||
| Education (year) | 10.5 (1.5) | 10.7 (1.7)° | 9.4 (0.7)⁎ | 3.99 | 2,64 | pη2 = 0.11 | ||||||||
| Verbal IQ (MWT-B) | 107.2 (9.8) | 104.5 (11.8) | 98.2 (9.0)⁎ | 4.02 | 2,64 | pη2 = 0.11 | ||||||||
| ADHD-SR score | 6.7 (5.7) | 13.8 (8.6)⁎⁎ | 18.8 (9.0)⁎⁎⁎ | 16.24 | 2,64 | pη2 = 0.34 | ||||||||
| BDI score | 2.6 (3.0) | 8.2 (8.2)⁎⁎ | 10.2 (9.5)⁎⁎⁎ | 9.74 | 2,64 | pη2 = 0.23 | 2.4 (4.7) | 5.7 (5.4) | 10.5 (11.4)⁎⁎ | 7.59 | 2,64 | pη2 = 0.19 | ||
| Cocaine | ||||||||||||||
| Times per week | – | 2.4 (2.0) n = 14 | 2.7 (1.9) | 0.44 | 25 | 0.66 | d = 0.17 | – | 0.6 (0.9) | 2.6 (2.2) | 3.09 | 27 | d = 1.27 | |
| Grams per week | – | 1.9 (1.4) | 5.9 (13.5) | 1.15 | 27 | 0.26 | d = 0.54 | – | 0.7 (1.3) | 4.7 (8.8) | 1.68 | 27 | 0.12 | d = 0.79 |
| Years of use | – | 7.5 (5.6) | 8.6 (5.2) | 0.56 | 27 | 0.58 | d = 0.21 | – | 9.0 (6.2) | 10.2 (6.2) | 0.54 | 27 | 0.60 | d = 0.20 |
| Cumulative dose (g) | – | 811 (929) | 1966 (2125) | 1.87 | 27 | 0.08 | d = 0.76 | – | 80 (90) n = 14 | 290 (696) | 1.12 | 26 | 0.27 | d = 0.53 |
| Maximum dose (g/d) | – | 4.5 (3.0) | 3.9 (3.5) | 0.47 | 27 | 0.64 | d = 0.18 | – | 2.2 (1.7) | 3.7 (4.6) | 0.94 | 20 | 0.36 | d = 0.46 |
| Last consumption (d) | – | 10 (15) n = 14 | 10 (11) | 0.11 | 26 | 0.92 | d = 0.04 | – | 54 (110) n = 13 | 6 (5) | 1.57 | 25 | 0.14 | d = 0.84 |
| Cocaine craving | – | 30.1 (15.7) n = 14 | 26.1 (11.8) n = 13 | 0.76 | 25 | 0.46 | d = 0.30 | – | 15.5 (6.7) | 29.4 (17.2) n = 13 | 2.75 | 26 | d = 1.17 | |
| Hair analysis (ng/mg) | ||||||||||||||
| Cocainetotal | – | 13.3 (15.6) | 27.7 (40.6) | 1.23 | 23 | 0.23 | d = 0.51 | – | 4.9 (6.0) | 52.2 (37.8) | 4.46 | 26 | d = 2.15 | |
| Cocaine | – | 9.9 (11.1) | 21.0 (30.9) | 1.25 | 23 | 0.22 | d = 0.53 | – | 3.7 (4.6) | 37.8 (28.4) | 4.28 | 26 | d = 2.07 | |
| Benzoylecgonine | – | 3.1 (4.3) | 6.2 (9.2) | 1.12 | 23 | 0.28 | d = 0.46 | – | 1.1 (1.5) | 13.5 (11.0) | 4.02 | 26 | d = 1.99 | |
| Cocaethylene | – | 0.6 (1.0) | 0.6 (0.6) | 0.14 | 23 | 0.89 | d = 0.06 | – | 0.5 (0.6) | 1.5 (1.7) | 2.12 | 26 | 0.05 | d = 0.91 |
| Norcocaine | – | 0.3 (0.4) | 0.5 (0.6) | 1.04 | 23 | 0.31 | d = 0.42 | – | 0.1 (0.1) | 0.9 (0.6) | 4.59 | 26 | d = 2.09 | |
| Urine toxicology (neg/pos) | 38/0 | 8/7 | 7/7 | 0.03 | 1 | 0.86 | V = 0.03 | 38/0 | 11/4 | 6/8 | 2.77 | 1 | 0.10 | V = 0.31 |
| Alcohol | ||||||||||||||
| Grams per week | 77.9 (110.7) | 265.0 (598.4) | 306.2 (607.0) | 2.24 | 2,64 | 0.12 | pη2 = 0.07 | 61.2 (69.2) | 135.5 (131.2)° | 333.6 (414.3)⁎⁎⁎ | 9.17 | 2,64 | pη2 = 0.22 | |
| Years of use | 11.0 (6.2) | 12.3 (7.7) | 13.4 (6.9) | 0.65 | 2,61 | 0.53 | pη2 = 0.02 | 12.4 (6.6) n = 35 | 14.1 (8.5) | 15.0 (7.4) | 0.78 | 2,61 | 0.46 | pη2 = 0.03 |
| Nicotine | ||||||||||||||
| Smoking (yes/no) | 27/11 | 12/3 | 14/0 | 5.20 | 2 | 0.07 | V = 0.28 | 28/10 | 12/3 | 14/0 | 4.54 | 2 | 0.10 | V = 0.26 |
| Cigarettes per day | 5.0 (6.2) | 9.9 (11.3) | 12.5 (8.1)⁎ | 5.33 | 2,64 | pη2 = 0.14 | 4.7 (6.4) | 10.3 (14.2) | 11.8 (7.5)⁎ | 4.32 | 2,64 | pη2 = 0.12 | ||
| Years of use | 7.1 (6.9) | 9.1 (8.4) | 14.5 (6.1)⁎⁎ | 5.42 | 2,64 | pη2 = 0.15 | 8.1 (7.5) | 10.6 (9.3) | 16.1 (6.7)⁎⁎ | 5.46 | 2,64 | pη2 = 0.15 | ||
| Cannabis | ||||||||||||||
| Grams per week | 0.0 (0.2) | 2.3 (7.2) | 2.4 (5.0) | 2.59 | 2,64 | 0.08 | pη2 = 0.08 | 0.1 (0.2) | 0.2 (0.5)° | 1.5 (2.4) ⁎⁎ | 8.03 | 2,64 | pη2 = 0.20 | |
| Years of use | 3.7 (5.6) | 7.9 (8.7) | 12.9 (6.6)⁎⁎⁎ | 10.25 | 2,63 | pη2 = 0.25 | 3.9 (5.8) n = 37 | 8.9 (9.9) | 13.6 (7.1)⁎⁎⁎ | 9.89 | 2, 63 | pη2 = 0.24 | ||
| Cumulative dose (g) | 73 (228) n = 37 | 1719 (2226) | 3324 (4519)⁎⁎⁎ | 10.66 | 2,63 | pη2 = 0.25 | 1.8 (7.1) n = 37 | 30.0 (53.6) | 50.5 (70.3)⁎⁎ | 8.11 | 2,64 | pη2 = 0 0.20 | ||
| Last consumption (d) | 58 (61) n = 10 | 15 (20) | 22 (17) | 3.24 | 2,24 | 0.06 | pη2 = 0.21 | 69 (63) | 21 (36)⁎ n = 10 | 11 (11)⁎⁎ n = 12 | 6.00 | 2,30 | 0.006 | pη2 = 0.29 |
| Urine toxicology (neg/pos) | 37/1 | 11/4 | 11/3 | 7.42 | 2 | V = 0.33 | 37/1 | 12/3 | 11/3 | 5.75 | 2 | 0.06 | V = 0.29 | |
| Amphetamine | ||||||||||||||
| Grams per week | 0.0 (0.0) | 0.3 (0.5)⁎⁎° n = 14 | 0.0 (0.1) | 6.16 | 2,63 | pη2 = 0.16 | 0.0 (0.0) | 0.0 (0.0)° | 0.1 (0.2)⁎⁎ | 7.28 | 2,64 | pη2 = 0.19 | ||
| Years of use | 0.0 (0.0) | 4.0 (4.2)⁎⁎⁎ | 2.1 (2.9)⁎ n = 13 | 16.46 | 2,63 | pη2 = 0.34 | 0.1 (0.5) | 4.4 (4.4)⁎⁎⁎ | 2.4 (3.0)⁎ n = 13 | 17.05 | 2,63 | pη2 = 0.35 | ||
| Cumulative dose (g) | 0 (0) | 75 (128) | 154 (307)⁎⁎ | 5.63 | 2,64 | pη2 = 0.15 | 0.1 (0.8) | 9.1 (31.8) | 3.7 (5.5) | 1.93 | 2, 65 | 0.16 | pη2 = 0.06 | |
| Last consumption (d) | – | 27.5 (24.9) n = 8 | 67.7 (70.8) n = 5 | 2.25 | 1,11 | 0.16 | pη2 = 0.17 | 30 (−) n = 1 | 49 (45) | 37 (48) n = 7 | 0.16 | 2,12 | 0.86 | pη2 = 0.03 |
| Hair analysis (ng/mg) | 0.0 (0.0) | 1.2 (3.3) | 0.6 (1.4) | 2.42 | 2,57 | 0.10 | pη2 = 0.08 | 0.0 (0.0) | 0.2 (0.4) | 0.5 (1.3) | 3.06 | 2,62 | 0.05 | pη2 = 0.09 |
| Urine toxicology (neg/pos) | 38/0 | 15/0 | 15/0 | – | – | – | – | 38/0 | 14/1 | 13/1 | 2.71 | 2 | 0.26 | V = 0.20 |
| MDMA | ||||||||||||||
| Tablets per week | 0.0 (0.0) | 0.2 (0.4) | 0.2 (0.5) | 2.58 | 2,64 | 0.08 | pη2 = 0.07 | 0.0 (0.0) | 0.1 (0.2)°° n = 14 | 0.8 (1.2)⁎⁎⁎ | 11.55 | 2,63 | pη2 = 0.27 | |
| Years of use | 0.1 (0.6) | 4.7 (5.4)⁎⁎⁎ | 3.9 (4.8)⁎⁎ n = 13 | 13.32 | 2,63 | pη2 = 0.30 | 0.2 (1.1) | 5.3 (6.1)⁎⁎⁎ | 4.6 (5.0)⁎⁎ n = 13 | 13.46 | 2,64 | pη2 = 0.30 | ||
| Cumulative dose (tablet) | 0 (2) | 107 (210)° | 598 (1011)⁎⁎⁎ n = 13 | 8.52 | 2,63 | pη2 = 0.21 | 0.6 (3.5) | 4.0 (8.6)°°° | 30.6 (36.0)⁎⁎⁎ | 16.54 | 2,64 | pη2 = 0.34 | ||
| Last consumption (d) | – | 51.0 (44.4) n = 6 | 78.2 (67.4) n = 7 | 0.71 | 1,11 | pη2 = 0.06 | 91 (−) n = 1 | 34 (18) n = 7 | 39 (55) n = 10 | 0.74 | 2,15 | 0.49 | pη2 = 0.09 | |
| Hair analysis (ng/mg) | 0.0 (0.0) | 0.2 (0.3)° | 1.2 (2.3)⁎⁎ | 6.52 | 2,57 | pη2 = 0.19 | 0.0 (0.0) | 0.2 (0.3) | 1.2 (3.3)⁎ | 3.59 | 2,63 | pη2 = 0.10 | ||
| Methylphenidate | ||||||||||||||
| Cumulative dose (tablet) | 3 (20) | 70 (262) | 214 (524)⁎ n = 13 | 3.20 | 2,63 | pη2 = 0.09 | 0.00 (0.00) | 28.4 (106.4) n = 14 | 20.7 (70.7) | 1.51 | 2,62 | 0.23 | pη2 = 0.05 | |
| Hair analysis (ng/mg) | 0.0 (0.0) | 0.0 (0.0) n = 12 | 0.0 (0.0) n = 10 | 1.65 | 2,49 | 0.20 | pη2 = 0.06 | 0.0 (0.0) | 0.1 (0.3) | 0.0 (0.0) | 1.70 | 2,63 | 0.19 | pη2 = 0.05 |
Means and SD of all groups (controls, decreasers and sustained users) for both measurement time points.
Significant P values are shown in bold.
Abbreviations: ADHD-SR = ADHD self-rating scale; BDI=Beck Depression Inventory; bl = blonde; blk = black; br = brown; d = day; g = gram; MDMA = 3,4methylenedioxymethamphetamine (“ecstasy”); mg = milligram; MWT-B = Mehrfachwahl-Wortschatz-Intelligenztest; ng = nanogram.
ANVOA group comparisons with significant Sidak post-hoc tests (cocaine user groups vs. controls: *P < .05, **P < .01,***P < .001; Decreasers vs. Sustained Users: °P < .05, °°P < .01,°°°P < .001.
χ2-test for frequency data (cocaine user groups only/all groups); Kramer's V reported as effect-size.
t-test (independent, two-tailed, cocaine users only); Cohen's d reported as effect-size.
Hair samples for four controls and four cocaine users are missing at baseline. At follow-up, hair sample for one sustained user is missing.
Average of use over the last six months.
At baseline the total cumulative dose across lifetime and at follow-up the total dose of cocaine consumed between the two measurement points are meant.
Urine tests classifications (neg/pos) are based on the following cutoff values: amphetamine = 300 ng/ml; cocaine = 150 ng/ml; tetrahydrocannabinol = 50 ng/ml (Substance Abuse and Mental Health Services Administration, 2008). The frequency tests for amphetamine and cannabis included all three groups, whereas for cocaine only the two cocaine user groups.
Days passed until last consumption were averaged only for subjects using the substance within the last six months.
Data for one participant is missing.
Data for 2 participants are missing.
Fig. 3Changes in cortical thickness.
Change in cortical thickness (in mm) from baseline to follow-up. Superior frontal gyrus: Decreasers P = .018 Sustained Users P = .16; Middle frontal gyrus: Decreasers P = .009 Sustained Users P = .15; Inferior frontal gyrus: Decreasers P = .022 Sustained Users P = .39;
Sidak post-hoc tests: *P < .05. All analyses were corrected for verbal IQ, ADHD-SR score, the amount of alcohol consumed between baseline and follow-up, and the time interval between the two measurements.
Fig. 4Changes in attention performance.
Change in sustained attention performance from baseline to follow-up. The analysis was corrected for verbal IQ, ADHD-SR score, the amount of alcohol consumed between baseline and follow-up, and the time interval between the two measurements. The follow-up values were additionally adjusted for test-retest effects. Decreasers P = .00003 Sustained Users P = .11;
Sidak post-hoc tests: *P < .05.